These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
136 related articles for article (PubMed ID: 9527404)
1. Aminoguanidine inhibits advanced glycation end products formation on beta2-microglobulin. Hou FF; Boyce J; Chertow GM; Kay J; Owen WF J Am Soc Nephrol; 1998 Feb; 9(2):277-83. PubMed ID: 9527404 [TBL] [Abstract][Full Text] [Related]
2. Molecular heterogeneity of amyloid beta2-microglobulin and modification with advanced glycation end products. Mironova R; Niwa T J Chromatogr B Biomed Sci Appl; 2001 Jul; 758(1):109-15. PubMed ID: 11482729 [TBL] [Abstract][Full Text] [Related]
3. Implication of an increased oxidative stress in the formation of advanced glycation end products in patients with end-stage renal failure. Miyata T; Wada Y; Cai Z; Iida Y; Horie K; Yasuda Y; Maeda K; Kurokawa K; van Ypersele de Strihou C Kidney Int; 1997 Apr; 51(4):1170-81. PubMed ID: 9083283 [TBL] [Abstract][Full Text] [Related]
4. Ultrastructural localization of advanced glycation end products and beta2-microglobulin in dialysis amyloidosis. Brancaccio D; Gallieni M; Niwa T; Braidotti P; Coggi G J Nephrol; 2000; 13(2):129-36. PubMed ID: 10858976 [TBL] [Abstract][Full Text] [Related]
5. Aminoguanidine inhibits albuminuria, but not the formation of advanced glycation end-products in skin collagen of diabetic rats. Degenhardt TP; Fu MX; Voss E; Reiff K; Neidlein R; Strein K; Thorpe SR; Baynes JW; Reiter R Diabetes Res Clin Pract; 1999 Feb; 43(2):81-9. PubMed ID: 10221660 [TBL] [Abstract][Full Text] [Related]
6. Amyloid beta 2-microglobulin is modified with N epsilon-(carboxymethyl)lysine in dialysis-related amyloidosis. Niwa T; Sato M; Katsuzaki T; Tomoo T; Miyazaki T; Tatemichi N; Takei Y; Kondo T Kidney Int; 1996 Oct; 50(4):1303-9. PubMed ID: 8887292 [TBL] [Abstract][Full Text] [Related]
7. Transforming growth factor-beta is involved in the pathogenesis of dialysis-related amyloidosis. Matsuo K; Ikizler TA; Hoover RL; Nakamoto M; Yasunaga C; Pupim LB; Hakim RM Kidney Int; 2000 Feb; 57(2):697-708. PubMed ID: 10652049 [TBL] [Abstract][Full Text] [Related]
8. Amyloid beta 2-microglobulin is modified with imidazolone, a novel advanced glycation end product, in dialysis-related amyloidosis. Niwa T; Katsuzaki T; Miyazaki S; Momoi T; Akiba T; Miyazaki T; Nokura K; Hayase F; Tatemichi N; Takei Y Kidney Int; 1997 Jan; 51(1):187-94. PubMed ID: 8995733 [TBL] [Abstract][Full Text] [Related]
9. Identification of pentosidine as a native structure for advanced glycation end products in beta-2-microglobulin-containing amyloid fibrils in patients with dialysis-related amyloidosis. Miyata T; Taneda S; Kawai R; Ueda Y; Horiuchi S; Hara M; Maeda K; Monnier VM Proc Natl Acad Sci U S A; 1996 Mar; 93(6):2353-8. PubMed ID: 8637877 [TBL] [Abstract][Full Text] [Related]
10. Interaction between beta 2-microglobulin and advanced glycation end products in the development of dialysis related-amyloidosis. Hou FF; Chertow GM; Kay J; Boyce J; Lazarus JM; Braatz JA; Owen WF Kidney Int; 1997 May; 51(5):1514-9. PubMed ID: 9150467 [TBL] [Abstract][Full Text] [Related]
11. The effect of an insulin releasing agent, BTS 67582, on advanced glycation end product formation in vitro. Simpson AE; Jones RB Life Sci; 1999; 64(16):1427-34. PubMed ID: 10321722 [TBL] [Abstract][Full Text] [Related]
12. Modification of beta 2-microglobulin with D-glucose or 3-deoxyglucosone inhibits A beta 2M amyloid fibril extension in vitro. Hashimoto N; Naiki H; Gejyo F Amyloid; 1999 Dec; 6(4):256-64. PubMed ID: 10611946 [TBL] [Abstract][Full Text] [Related]
14. Inhibition of advanced protein glycation by a Schiff base between aminoguanidine and pyridoxal. Taguchi T; Sugiura M; Hamada Y; Miwa I Eur J Pharmacol; 1999 Aug; 378(3):283-9. PubMed ID: 10493104 [TBL] [Abstract][Full Text] [Related]
15. Chronic dosing with aminoguanidine and novel advanced glycosylation end product-formation inhibitors ameliorates cross-linking of tail tendon collagen in STZ-induced diabetic rats. Kochakian M; Manjula BN; Egan JJ Diabetes; 1996 Dec; 45(12):1694-700. PubMed ID: 8922353 [TBL] [Abstract][Full Text] [Related]
16. In vivo and in vitro evidence for the glycoxidation of low density lipoprotein in human atherosclerotic plaques. Imanaga Y; Sakata N; Takebayashi S; Matsunaga A; Sasaki J; Arakawa K; Nagai R; Horiuchi S; Itabe H; Takano T Atherosclerosis; 2000 Jun; 150(2):343-55. PubMed ID: 10856526 [TBL] [Abstract][Full Text] [Related]
17. Mechanism of the inhibitory effect of OPB-9195 [(+/-)-2-isopropylidenehydrazono-4-oxo-thiazolidin-5-yla cetanilide] on advanced glycation end product and advanced lipoxidation end product formation. Miyata T; Ueda Y; Asahi K; Izuhara Y; Inagi R; Saito A; VAN Ypersele DE Strihou C; Kurokawa K J Am Soc Nephrol; 2000 Sep; 11(9):1719-1725. PubMed ID: 10966497 [TBL] [Abstract][Full Text] [Related]
18. Mechanistic studies of advanced glycosylation end product inhibition by aminoguanidine. Edelstein D; Brownlee M Diabetes; 1992 Jan; 41(1):26-9. PubMed ID: 1727735 [TBL] [Abstract][Full Text] [Related]
19. Beneficial effect of Corni Fructus, a constituent of Hachimi-jio-gan, on advanced glycation end-product-mediated renal injury in Streptozotocin-treated diabetic rats. Yamabe N; Kang KS; Goto E; Tanaka T; Yokozawa T Biol Pharm Bull; 2007 Mar; 30(3):520-6. PubMed ID: 17329849 [TBL] [Abstract][Full Text] [Related]
20. Advanced glycation end products induce crosslinking of collagen in vitro. Sajithlal GB; Chithra P; Chandrakasan G Biochim Biophys Acta; 1998 Sep; 1407(3):215-24. PubMed ID: 9748585 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]